

# LIFE SAVING DRUGS PROGRAM EXPERT PANEL

## TENTH MEETING: 8 October 2021

### AGENDA

#### 1. Standing business

- 1.1. Welcome and apologies
- 1.2. Declaration of potential or actual Conflicts of Interest
- 1.3 Correspondence
- 1.4 Report from the Secretariat

#### 2 Reviews of existing LSDP medicines

##### 24 month reviews – discussion of **draft** reports

- 2.1 Migalastat (Galafold®) - for the treatment of Fabry Disease
- 2.2 Cerliponase alfa (Brineura®) – for the treatment of Late Infantile Onset Batten (CLN2) Disease

#### 3 Applications for new LSDP medicines

- 1.3. Asfotase alfa (Strensiq®) – for the treatment of perinatal and infantile-onset hypophosphatasia

#### 4 Other business